Product Data Sheet

UP202-56

 Cat. No.:
 HY-U00226

 CAS No.:
 163838-04-8

 Molecular Formula:
 C₃₄H₃₈N₆O₄


Molecular Weight: 594.7

Target: Adenosine R

Target: Adenosine Receptor
Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



BIOLOGICAL ACTIVITY

Description	UP202-56 is an adenosine analogue, which is an adenosinergic agonist.
IC ₅₀ & Target	Adenosine Receptor $^{[1][2]}$
In Vitro	The effects of oral administration of UP202-56, an adenosine analogue, are assessed on carrageenan-induced spinal c-Fos protein expression and peripheral oedema. Oral UP202-56 (10, 30 or 50 mg/kg) dose-dependently reduces the number of carrageenan-induced c-Fos like immunoreactivity (c-Fos-LI) neurons (r=0.931. P<0.0001), with the highest dose of UP202-56 producing 72±4% reduction of the total number of carrageenan-induced spinal c-Fos-LI neurons, and 12±3% and 33±6% of reduction of control carrageenan oedema at paw and ankle levels, respectively. UP202-56 dose-dependently reduces the spinal c-Fos protein expression in carrageenan model of inflammatory pain ^[1] . UP202-56 is an adenosinergic agonist ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Honoré P, et al. UP 202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression. Pain. 1998 Apr;75(2-3):281-93.

[2]. Camborde, Francois, et al. PHARMACEUTICAL COMBINATION WITH ANALGESIC ACTIVITY, CONTAINING AN ADENOSINERGIC AGONIST AND A COMPOUND SELECTED FROM OPIATES, BENZODIAZEPINES AND NMDA ANTAGONISTS. Patent Application WO/1999/029347.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA